Dr. Dong-Wan Kim
Claim this profileSeoul National University Hospital
Studies Non-Small Cell Lung Cancer
Studies Tumors
17 reported clinical trials
22 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage III
Stage IV
PD-L1 positive
2Tumors
Stage IV
Stage III
ROS1 positive
Clinical Trials Dong-Wan Kim is currently running
GSK6097608 + Dostarlimab
for Advanced Cancers
This trial tests new drugs alone or in combination to treat people with advanced solid tumors. The drugs either attack cancer cells directly or help the immune system fight cancer. The study includes Japanese and Chinese participants.
Recruiting1 award Phase 112 criteria
GSK4381562
for Cancer
This trial tests a new drug called GSK4381562 in patients with recurring or spreading tumors who have no other treatment options. It will see how the drug is processed by the body, its safety, and any immune responses it might cause.
Recruiting2 awards Phase 13 criteria
More about Dong-Wan Kim
Clinical Trial Related3 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Dong-Wan Kim has experience with
- Dostarlimab
- Selpercatinib
- GSK4428859A
- TPX-0131
- NVL-520
- Repotrectinib (TPX-0005)
Breakdown of trials Dong-Wan Kim has run
Non-Small Cell Lung Cancer
- A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
- The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
- Selpercatinib for Non-Small Cell Lung Cancer
Tumors
Lung Cancer
- A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
- The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
- Selpercatinib for Advanced Non-Small Cell Lung Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dong-Wan Kim specialize in?
Dong-Wan Kim focuses on Non-Small Cell Lung Cancer and Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Dong-Wan Kim currently recruiting for clinical trials?
Yes, Dong-Wan Kim is currently recruiting for 7 clinical trials in Seoul Jongno-gu. If you're interested in participating, you should apply.
Are there any treatments that Dong-Wan Kim has studied deeply?
Yes, Dong-Wan Kim has studied treatments such as Dostarlimab, Selpercatinib, GSK4428859A.
What is the best way to schedule an appointment with Dong-Wan Kim?
Apply for one of the trials that Dong-Wan Kim is conducting.
What is the office address of Dong-Wan Kim?
The office of Dong-Wan Kim is located at: Seoul National University Hospital, Seoul, Jongno-gu 03080 Korea, Republic of. This is the address for their practice at the Seoul National University Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.